5. **Idell S**, Gonzalez K, Bradford H, *et al*. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. *Am Rev Respir Dis* 1987;**136**:1466–74.
6. **Idell S**, Koenig KB, Fair DS, *et al*. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. *Am J Physiol* 1991;**261**:L240–8.
7. **Schultz MJ**, Millo J, Levi M, *et al*. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. *Thorax* 2004;**59**:130–5.
8. **Bastarache JA**, Wang L, Geiser T, *et al*. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. *Thorax* 2007;**62**:608–16.
9. **Miller DL**, Welty-Wolf K, Carraway MS, *et al*. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. *Am J Respir Cell Mol Biol* 2002;**26**:650–8.
10. **Marshall BC**, Sageser DS, Rao NV, *et al*. Alveolar epithelial cell plasminogen activator. Characterization and regulation. *J Biol Chem* 1990;**265**:8198–204.
11. **Idell S**. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. *Crit Care Med* 2002;**30**:S274–80.
12. **Yamamoto K**, Loskutoff DJ. Extrahepatic expression and regulation of protein C in the mouse. *Am J Pathol* 1998;**153**:547–55.
13. **Choi G**, Schultz MJ, Levi M, *et al*. Protein C in pneumonia. *Thorax* 2005;**60**:705–6.
14. **Hataji O**, Taguchi O, Gabazza EC, *et al*. Activation of protein C pathway in the airways. *Lung* 2002;**180**:47–59.
15. **Bernard GR**, Vincent JL, Laterre PF, *et al*. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001;**344**:699–709.
16. **Abraham E**, Laterre PF, Garg R, *et al*. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. *N Engl J Med* 2005;**353**:1332–41.
17. **Nadel S**, Goldstein B, Williams MD, *et al*. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. *Lancet* 2007;**369**:836–43.
18. **Dellinger RP**, Levy MM, Carlet JM, *et al*. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008;**36**:296–327.
19. **Laterre PF**, Garber G, Levy H, *et al*. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. *Crit Care Med* 2005;**33**:952–61.
20. **van der Poll T**, Levi M, Nick JA, *et al*. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. *Am J Respir Crit Care Med* 2005;**171**:1125–8.
21. **Liu KD**, Levitt J, Zhuo H, *et al*. Randomized clinical trial of activated protein C for the treatment of acute lung injury. *Am J Respir Crit Care Med* 2008;**178**:618–23.
22. **Looney MR**, Esmon CT, Matthay MA. Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury in mice. *Thorax* 2009;**64**:114–20.
23. **Barazzzone C**, Belin D, Piquet PF, *et al*. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. *J Clin Invest* 1996;**98**:2666–73.
24. **Choi G**, Hofstra JJ, Roelofs JJ, *et al*. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during *Pseudomonas aeruginosa* pneumonia in rats. *Crit Care Med* 2007;**35**:1362–8.
25. **Choi G**, Vlaar AP, Schouten M, *et al*. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. *Eur Respir J* 2007;**30**:423–8.
26. **Choi G**, Hofstra JJ, Roelofs JJ, *et al*. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during *Streptococcus pneumoniae* pneumonia in rats. *Crit Care Med* 2008;**36**:204–10.
27. **Hofstra JJ**, Cornet AD, Vlaar AP, *et al*. Nebulized antithrombin attenuates bacterial outgrowth in experimental streptococcus pneumoniae pneumonia in rats (abstract). *Intensive Care Med* 2008;**34**:S263.
28. **Murakami K**, McGuire R, Cox RA, *et al*. Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. *Shock* 2002;**18**:236–41.
29. **Enkhbaatar P**, Cox RA, Traber LD, *et al*. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. *Crit Care Med* 2007 Oct 23 [Epub ahead of print].
30. **Enkhbaatar P**, Esehie A, Wang J, *et al*. Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation. *Clin Sci (Lond)* 2008;**114**:321–9.
31. **Bendstrup KE**, Chambers CB, Jensen JI, *et al*. Lung deposition and clearance of inhaled (99m)Tc-heparin in healthy volunteers. *Am J Respir Crit Care Med* 1999;**160**:1653–8.
32. **Bendstrup KE**, Gram J, Jensen JI. Effect of inhaled heparin on lung function and coagulation in healthy volunteers. *Eur Respir J* 2002;**19**:606–10.
33. **Dixon B**, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. *Crit Care* 2008;**12**:R64.
34. **Desai MH**, Mlcak R, Richardson J, *et al*. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcysteine therapy. *J Burn Care Rehabil* 1998;**19**:210–2.

Pleural ultrasound

David Feller-Kopman

The use of hand-held portable ultrasound (US) has probably had more of an impact in the care of patients with pleural effusions than any other development since Light introduced a method for distinguishing transudative from exudative effusions in 1972.¹ The advantages of US for the evaluation of pleural effusions include the ability to provide real-time guidance for procedures, the absence of radiation, portability and the ability to perform dynamic evaluations. US is more sensitive than chest radiography for the detection of pleural fluid and may be better than chest CT scanning for differentiating pleural effusion from pleural thickening. The use of US has also been associated with a reduction in “near misses” as well as an increased yield, even in experienced hands.² Because of these benefits, the use of US by non-radiologists has increased tremendously over the last

few years. The American Board of Internal Medicine “strongly recommends” obtaining proficiency in the use of US to guide thoracentesis for fellows in pulmonary and critical care training programmes (<http://www.abim.org/certification/policies/imss/ccm.aspx>). Likewise, the American College of Emergency Physicians,³ the American College of Surgeons⁴ and the Royal College of Radiology⁵ have all issued statements regarding the incorporation of US in the care of patients with pleural effusions.

There have been several recent reviews of the use of US to guide thoracentesis^{6–7} and, when compared with historical controls, the use of US is associated with a significant reduction in complications as well as improved yield.^{2–9} In addition, the sonographic characteristics of effusions have been shown to correlate with underlying pathology. Complex effusions (with or without septae) and homogeneously echogenic effusions are usually exudative, whereas anechoic effusions could be either exudative or transudative.^{10–11} The sonographic characteristics of effusions have

also been found to predict the need for pleural intervention in patients with empyema.¹² To date, however, only the presence of a pleural mass and the “echogenic swirling pattern” have been suggestive of the presence of a malignant pleural effusion (MPE).^{13–14}

In this issue of *Thorax*, Qureshi and colleagues,¹⁵ by using a systematic approach to the patient with suspected MPE, were able to accurately identify patients with malignant and benign disease (see page 139). Thoracic US was performed without clinical history and considered consistent with MPE if diaphragmatic/parietal pleural nodules, pleural thickening >1 cm or hepatic metastases were found. The inability to resolve the five distinct layers of the diaphragm which are normally easily seen and a diaphragm thickness >7 mm were also associated with malignant effusions. Benign disease was considered present when infection was confirmed or patients had a clinical follow-up of at least 12 months. Thoracic US correctly diagnosed 26/33 patients with malignant disease and 19/19 patients with benign disease (sensitivity 79%, specificity 100%, positive predictive value 100% and negative predictive value 73%) for differentiating malignant from benign disease. In comparison with chest CT scanning as

Correspondence to: Dr D Feller-Kopman, Interventional Pulmonology, Johns Hopkins Hospital, 1830 East Monument St, Fifth Floor, Baltimore, MD 21205, USA; dfellerk@jhmi.edu

the gold standard, thoracic US performed quite well. In six of the seven false negative US examinations, chest CT identified malignancy based on parenchymal opacities, adenopathy or the identification of metastatic disease.

Although well conducted, there are several methodological issues that may limit generalisability of the results. First, there was a high incidence of MPE (especially mesothelioma) in this study population. The propensity of mesothelioma to cause thickening of the pleura and diaphragm, as opposed to other malignancies that may cause isolated pleural nodularity, may have biased the performance characteristics of US in this study. This issue will need to be more clearly defined in a larger study with a more typical distribution of MPE not caused by mesothelioma. Second, the US examinations were performed by two experienced radiologists. Although US is used by many non-radiologists to examine the pleural space, the expertise of the authors may have allowed them to identify abnormalities that would have been missed by their non-radiology colleagues. In addition to using a standard 3.5 MHz curvilinear transducer, the authors used a high-frequency 8–15 MHz linear array transducer which has significantly higher resolution. Likewise, the US equipment used in the study is more sophisticated than some of the hand-held units currently used by the non-radiology community. It would have also been interesting if the authors could have confirmed the utility of the “echogenic swirling sign” in their patient population.

One of the largest benefits of US in the evaluation of patients with suspected

MPE is that it is a non-invasive imaging modality that does not expose the patient to radiation. As such, US should be positioned after the clinical examination or after a standard chest radiograph in the algorithm of evaluating patients with pleural effusions. Performing chest US prior to obtaining a chest CT scan will provide the physician with valuable clinical information including the ability to narrow one differential diagnosis, guide pleural drainage and potentially predict the ability of the lung to fully re-expand. Draining the effusion before the chest CT scan will reduce the effects of compressive atelectasis and aid in the evaluation of the underlying parenchyma. A contrary argument, however, is that the presence of pleural fluid improves the sensitivity of the chest CT scan for evaluating pleural thickening and nodularity. Likewise, chest CT scanning has the obvious benefit of identifying parenchymal opacities invisible to US and can simultaneously provide information about mediastinal lymph nodes and extrathoracic disease.

One of the lessons the reader should take home from this study is that chest ultrasonography should proceed in a standardised fashion with attention to and documentation of specific details (see online supplement to paper by Qureshi *et al*¹⁵). By using a systematic approach, important details will not be overlooked and the full benefits of pleural US will be realised.

Competing interests: None.

Thorax 2009;**64**:97–98. doi:10.1136/thx.2008.107292

REFERENCES

1. Light RW, Macgregor MI, Luchsinger PC, *et al*. Pleural effusions: the diagnostic separation of transudates and exudates. *Ann Intern Med* 1972;**77**:507–13.
2. Diacon AH, Brutsche MH, Soler M. Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound. *Chest* 2003;**123**:436–41.
3. American College of Emergency Physicians. Use of ultrasound imaging by emergency physicians. *Ann Emerg Med* 2001;**38**:469–70.
4. American College of Surgeons. Ultrasound examinations by surgeons. 1998. http://www.facs.org/fellows_info/statements/st-31.html
5. Board of the Faculty of Clinical Radiology. *Ultrasound training recommendations for medical and surgical specialties*. London: Royal College of Radiology, 2005.
6. Mayo PH, Doelken P. Pleural ultrasonography. *Clin Chest Med* 2006;**27**:215–27.
7. Feller-Kopman D. Ultrasound-guided thoracentesis. *Chest* 2006;**129**:1709–14.
8. Mayo PH, Goltz HR, Tafreshi M, *et al*. Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation. *Chest* 2004;**125**:1059–62.
9. Grogan DR, Irwin RS, Channick R, *et al*. Complications associated with thoracentesis. A prospective, randomized study comparing three different methods. *Arch Intern Med* 1990;**150**:873–7.
10. Hirsch JH, Rogers JV, Mack LA. Real-time sonography of pleural opacities. *AJR Am J Roentgenol* 1981;**136**:297–301.
11. Yang PC, Luh KT, Chang DB, *et al*. Value of sonography in determining the nature of pleural effusion: analysis of 320 cases. *AJR Am J Roentgenol* 1992;**159**:29–33.
12. Chen KY, Liaw YS, Wang HC, *et al*. Sonographic septation: a useful prognostic indicator of acute thoracic empyema. *J Ultrasound Med* 2000;**19**:837–43.
13. Gorg C, Restrepo I, Schwert WB. Sonography of malignant pleural effusion. *Eur Radiol* 1997;**7**:1195–8.
14. Chian CF, Su WL, Soh LH, *et al*. Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies. *Chest* 2004;**126**:129–34.
15. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. *Thorax* 2009;**64**:139–43.

Traffic-related air pollution, genetics and asthma development in children

Thomas Sandström,¹ Frank J Kelly²

In recent years, air pollution has increasingly become recognised as a major

¹ Department of Respiratory Medicine and Allergy, University Hospital, Umea, Sweden; ² Environmental Research Group, School of Biomedical and Health Sciences, King's College, London, UK

Correspondence to: Professor T Sandström, Department of Respiratory Medicine and Allergy, University Hospital, Umea SE-901 85, Sweden; thomas.sandstrom@lung.umu.se

contributor to adverse health effects. Numerous studies have shown that poor air quality can adversely affect those with respiratory conditions such as asthma and chronic obstructive pulmonary disease and, more recently, cardiovascular conditions such as myocardial infarctions and stroke.¹ Wherever the location, air pollution has been shown to be associated with deterioration in

patients with these conditions, as well as with increased mortality.

In patients with asthma, air pollution increases symptoms, medication use, bronchoconstriction, emergency room admissions and hospitalisations. These effects are linked to pollutants such as ozone, nitrogen dioxide and particulate matter (PM) and, increasingly, the role of traffic-related air pollution has been highlighted. Traffic pollution consists of a complex mixture of particles and gases from gasoline and diesel engines, together with dust from wear of road surfaces, tyres and brakes. The coarse particles from road dust have been clearly associated with worsening of asthma and respiratory symptoms.² Motor engine particles from diesel engines have been linked with worsening of asthma and increased bronchial hyper-responsiveness,